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LETTERS
Revised British Society
of Gastroenterology
recommendation on the
diagnosis and management
of Barrett’s oesophagus with
low-grade dysplasia
The most recent guidelines for the man-
agement of Barrett’s oesophagus pub-
lished in 2014 recommended endoscopic
surveillance for patient with histological
evidence of low-grade dysplasia (LGD) on
random biopsies.1 In the last 2 years, new
evidence on the natural history of LGD in
Barrett’s oesophagus and on the safety
and efficacy of endoscopic treatment in
this subgroup of patients has been
published.
Duits et al have conducted a retrospect-
ive analysis of 293 patients with LGD
diagnosed in community hospitals.2
Following consensus review, the original
LGD diagnosis was confirmed in 27% of
cases, while the remaining of the cases
were downgraded to non-dysplastic
Barrett’s oesophagus or indefinite for dys-
plasia (IND). Patients with a LGD consen-
sus diagnosis had a progression rate to
high-grade dysplasia (HGD) or cancer of
9.1%/year over a median follow-up of
39 months. By contrast, patients whose
diagnosis was down-staged to either non-
dysplastic Barrett’s oesophagus or IND
had a conversion rate of 0.6% and 0.9%/
year, respectively (evidence grade: low).
This study reiterates the difficulty in
making a pathological diagnosis of LGD,
but also shows that confirmation by an
expert pathologist from a different institu-
tion associates with a substantially higher
risk of progression. In keeping with this
study, a recent meta-analysis found that
studies on cohorts with a low LGD/non-
dysplastic Barrett’s oesophagus ratios
(<0.15), indicative of a more stringent
and robust dysplasia diagnosis, reported a
significantly higher annual incidence of
cancer (0.76%, 95% CI 0.45% to 1.07%)
compared with studies with a ratio
>0.15, where many LGD cases were
likely overdiagnosed (0.32%; 95% CI
0.07% to 0.58%) (evidence grade: low).3
With regard to endoscopic treatment, a
recent multicentre randomized controlled
trial compared the outcome of 68 patients
with LGD treated with radiofrequency
ablation (RFA) with an equal number of
patients undergoing annual endoscopic
surveillance.4 The main inclusion criterion
was a diagnosis of LGD confirmed by a
central pathologist with extensive experi-
ence in Barrett’s oesophagus. Over a
3-year follow-up period, 1% of patients in
the treatment arm progressed to HGD or
cancer, compared with 26.5% in the
control arm (p<0.001) (evidence grade:
high). Complete eradication of dysplasia
and intestinal metaplasia by RFA was
achieved in 98% and 90%, respectively.
The most common complication was stric-
ture, which occurred in 12% of patients,
but this was successfully managed in all
patients with endoscopic dilatation.
Taken together, the new published data
suggest that a consensus diagnosis of LGD
by independent pathologists correlates
with a significant risk of progression to
HGD/cancer and that RFA significantly
reduces this risk. This strongly indicates
that endoscopic ablation, preferably with
RFA, is an appropriate treatment for
Barrett’s oesophagus with LGD (figure 1).
Due to the considerable diagnostic diffi-
culties, LGD should be diagnosed and
confirmed by an expert GI pathologist in
at least two endoscopes. Treatment
options should be discussed by an upper
GI multidisciplinary team (MDT) to
ensure pathology review and assess
patient fitness and endoscopic therapy
should be restricted to high volume
centres as per main 2014 guidelines. As
noted in the current guidelines, p53
immunohistochemistry can be a useful
diagnostic adjunct.
Therefore, the new recommendation on
the management of LGD in Barrett’s
oesophagus is:
Patients with LGD should have a repeat
endoscopy in 6 months’ time. If LGD is
found in any of the follow-up oesophago-
gastroduodenoscopy and is confirmed by
an expert GI pathologist in at least two
Figure 1 Updated flow chart for the management of dysplastic Barrett’s oesophagus. A
pathological finding of indefinite for dysplasia does not exclude the presence of dysplasia;
therefore, a 6-month follow-up is warranted. Endoscopic follow-up in 6 months is recommended
for LGD. If LGD is also found at follow-up endoscopy, even if not consecutive, provided that the
diagnosis of dysplasia on two occasions is confirmed by two independent GI pathologists (ideally
from a different institution), endoscopic ablation should be considered. A diagnosis of high-grade
dysplasia (HGD) also needs to be confirmed by a second GI pathologist. Patients with dysplasia
should be offered endoscopic therapy following discussion within MDT setting. LGD, low-grade
dysplasia; HGD, high-grade dysplasia; MDT, multidisciplinary team; OGD,
oesophagogastroduodenoscopy.
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sets of biopsies, the patient should be
offered endoscopic ablation therapy, pref-
erably with RFA, after review by the spe-
cialist MDT. If ablation is not undertaken,
6-monthly surveillance is recommended
(recommendation grade A for endoscopic
therapy and C for surveillance).
Agreement: A+ 56%, A 33%, U 0%, D
11%, D+ 0%.
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